5th International AIDS Conference Montreal, Quebec, Canada — Jun 4-9, 1989

Int Conf AIDS 1989 Jun 4-9; 5:215 (abstract no. Th.B.O.24)

Sidtis JJ, Thaler H, Brew BJ, Sadler AE, Keilp JG, Aranow HA, Price RW; Memorial Sloan-Kettering Cancer Center, NY, USA

OBJECTIVE: To estimate the time period between detection of equivocal and definite neurological signs and symptoms in a group of HIV-1 seropositive patients being followed for ADC.

METHODS: 132 patients who were ADC Stage 0.5 (equivocal/subclinical ADC) (J Infect Dis, 158: 1079-1083, 1988) who underwent serial evaluation on the Neuro-AIDS Study Group neurological history, examination, and neuropsychological battery served as subjects in this study. The time to progress to a Stage 1.0 or greater (definite neurological signs and symptoms) was determined using Kaplan-Meier estimates.

RESULTS: There was an average of 3.3 follow-up exams after the detection of equivocal/subclinical signs and symptoms, and the average follow-up time was 33 weeks. By 37 weeks, 25% of the patients had progressed to a Stage 1 or greater; by 59 weeks, 50% of the patients had progressed. A preliminary analysis of possible predictive variables revealed no differential progression rate as a function of the presence or absence of eye-movement abnormalities or limb-slowing.

CONCLUSIONS: These data provide a preliminary estimate of the high rate of progression from equivocal/subclinical to functionally significant ADC. Additional experience will be required to identify clinical and laboratory findings which more accurately predict neurological progression.

Keywords: AEGIS, AIDS Dementia Complex, Acquired Immunodeficiency Syndrome, HIV-1, CD4 Lymphocyte Count, Neurologic Examination, Magnetic Resonance Imaging, Human, diagnosis, abnormalities, ICA5

1989-06-04
ThBO24

Copyright © 1989 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.